Chugai Pharmaceutical revenue and financials

4519 · TSE · JPY

¥6,087.00−0.54%−¥33.00

Close · October 7, 2026

In the fiscal year ended December 2025, Chugai Pharmaceutical reported revenue of ¥1.26T (+7.46% year over year). Net income was ¥434.01B, a net margin of 34.5%.

Annual revenue · 2025: ¥1.26T

¥1.26T2022
¥1.11T2023
¥1.17T2024
¥1.26T2025

Fiscal year ending in December. Sources and method on the page Methodology and sources.

At a glance

Revenue growth: +7.46%; 2025 vs 2024
Net income growth: +12.06%; 2025 vs 2024
Net margin: 34.5%; 2024: 33.1%

Financial data

Amounts in millions of JPY; per-share values in JPY; shares in millions.

Income statement · Quarterly
Item	Q1 2026	Q1 2025
Basic EPS	70.13	59.09
Diluted EPS	70.13	59.08
Average shares (basic)	1,646	1,646
Average shares (diluted)	1,646	1,646